Literature DB >> 11758636

Enantioselective binding of disopyramide to alpha1-acid glycoprotein and its variants.

S Kishino1, S Itoh, T Nakagawa, K Miyazaki.   

Abstract

OBJECTIVE: alpha1-acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide (DP), which is a basic drug. The aim of this study was to elucidate the cause of the differences between the binding characteristics of DP enantiomers.
METHODS: The variants in human AAG were separated by hydroxyapatite chromatography. Binding of DP enantiomers to AAG variants was studied by the ultrafiltration method. The characteristics of the binding of DP enantiomers to total variants and each variant were examined by Scatchard analysis within a range of concentrations from 0.5 to 50.0 microg/ml.
RESULTS: The binding capacity of S-DP was significantly higher than that of R-DP in variant 3, although the binding capacities of DP enantiomers were almost the same in variant 2. On the other hand, the binding capacities for both S-DP and R-DP in variant 3 were significantly higher than those in variant 2. Furthermore, there was an almost 2.4-fold difference in the dissociation constant (Kd) between S-DP and R-DP in variant 3, although no significant difference was observed in the number of binding sites (N). In variant 2 no significant differences between DP enantiomers were observed in either the dissociation constant or number of binding sites per molecule of AAG. On the other hand, significant differences between variants 2 and 3 in the dissociation constant for both S-DP and R-DP were observed. The differences in dissociation constant between variants 2 and 3 were 4.0-fold in S-DP and 1.7-fold in R-DP.
CONCLUSION: The difference between the binding capacities of S-DP and R-DP is due to differences in the association of DP to variants 3-6, and the role of the variants 1 and 2 in the binding of drugs to AAG is minor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758636     DOI: 10.1007/s002280100354

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.

Authors:  Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

2.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.

Authors:  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.